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INTRODUCTION
Myeloablative chemoradiotherapy followed by autolo-
gous stem cell transplantation (autoSCT) is an accepted
treatment for various lymphohematopoietic malignancies,
including Hodgkin’s disease [1-3], non-Hodgkin’s lym-
phoma [4-6], and multiple myeloma [7,8]. The major
cause of treatment failure following autoSCT remains
relapse of the underlying disease, which occurs in 45% to
75% of patients with lymphoma, depending on the disease
and remission status at the time of transplantation. In
patients with myeloma, a continuing pattern of relapse has
been observed in most autoSCT series. Patients with long
disease-free intervals, limited prior therapy, and chemo-
therapy-sensitive disease might benefit from a second
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ABSTRACT
The use of myeloablative preparative therapy and allogeneic stem cell transplantation (alloSCT) as salvage therapy
for adult patients with relapsed hematologic malignancy after autologous stem cell transplantation (autoSCT) is gen-
erally unsuccessful due to very high treatment-related mortality rates. We evaluated the outcome of HLA-matched
related donor alloSCT following nonmyeloablative preparative therapy in 13 patients (median age, 38 years) with
relapsed hematologic malignancies (Hodgkin’s disease, n = 4; Hodgkin’s disease and advanced myelodysplastic syn-
drome, n = 1; non-Hodgkin’s lymphoma, n = 6; multiple myeloma, n = 2) after initial autoSCT. Median time from
autoSCT to alloSCT was 12 months (range, 3-24 months); 6 patients had chemotherapy-refractory disease following
autoSCT, 6 were in untreated relapse, and 1 had a partial response from salvage chemotherapy. Preparative therapy
consisted of cyclophosphamide, 150-200 mg/kg; peritransplantation anti-thymocyte globulin; thymic irradiation (in
patients who had not received previous mediastinal irradiation); and a very short course of cyclosporine as GVHD
prophylaxis. All patients achieved initial mixed chimerism as defined by greater than 1% donor peripheral white
blood cells. Seven patients, who had no evidence of GVHD, received prophylactic DLI beginning 5 to 6 weeks after
transplantation for conversion of mixed chimerism to full donor hematopoiesis and to optimize a graft-versus-tumor
effect. Six patients showed conversion to full donor chimerism and 1 lost the graft. Grade II or greater acute GVHD
occurred in 9 patients. Seven patients achieved a complete response; 6 had no response. The median survival time of
the 13 patients is currently 10 months (range, 3-39 months), with an overall survival probability at 2 years of 45%
(95% confidence interval [CI], 19%-73%) and a disease-free survival probability at 2 years of 37.5% (95% CI, 12%-
65%). Thus, this novel nonmyeloablative alloSCT strategy followed by prophylactic DLI was well tolerated and can
result in durable disease-free survival among patients with advanced hematologic malignancies after a failed
autoSCT. Further follow-up and evaluation of additional patients are required to conclusively establish the role of
this strategy in the treatment of hematologic malignancies after an autologous transplantation.
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SCT [9]. Allogeneic transplantation would theoretically
be preferable because it has an antitumor effect due to an
allogeneic graft-versus-host (GVH) response, which is
absent in autografting. However, transplantation-related
mortality following allogeneic transplantation in previous
autotransplant recipients has been extremely high, partic-
ularly in patients with lymphoma [10-12]. Alternative
strategies, such as nonmyeloablative chemotherapy and
allogeneic SCT (alloSCT) followed by donor leukocyte
infusion (DLI), need to be evaluated in patients with
relapsed hematologic malignancies after autoSCT, with the
aim of achieving a durable antitumor response while reduc-
ing transplantation-related mortality.
It has been demonstrated that mixed lymphohematopoi-
etic chimerism can be achieved in mice across full major
histocompatibility complex barriers and in large-animal
models after both myeloablative and nonmyeloablative
preparative regimens [13-17]. When nontolerant donor
leukocyte infusions are given to these mixed chimeras sev-
eral weeks following bone marrow transplantation (BMT),
they convert to full donor-type chimeras as a result of a
potent lymphohematopoietic GVH reaction, but GVH dis-
ease (GVHD) does not occur [18,19]. Furthermore, delayed
infusions of donor leukocytes have been proved to mediate a
powerful antitumor effect in murine fully allogeneic
chimeras [20,21] and in mixed chimeras [22] (M. Mapara et
al., unpublished data, 2001) without causing GVHD [20].
Thus, a delay in DLI in animals receiving a nonmyeloabla-
tive conditioning regimen can permit lymphohematopoietic
GVH reactions, which are associated with graft-versus-
tumor (GVT) effects, to occur without causing GVHD in
the nonlymphohematopoietic tissues. In human SCT, mixed
chimerism has occasionally been noted as an incidental
ﬁnding [23-28], and this ﬁnding has been shown to be asso-
ciated with less intensive preparative regimens and the sur-
vival of host stem cells [26,29]. In some clinical series, an
association has been observed between mixed chimerism
and a reduced incidence of acute GVHD [23,25,30,31].
Based on the principle of reduced transplantation-related
mortality associated with nonmyeloablative conditioning
therapy and the attempt to maximize the GVT effect of
delayed DLI while GVHD is abrogated, we have performed
HLA-matched or -mismatched donor transplantation in
patients with chemotherapy-refractory hematologic malignan-
cies using a nonmyeloablative preparative regimen consisting
of cyclophosphamide, peritransplantation anti-thymocyte
globulin, thymic irradiation, cyclosporine, and delayed
“prophylactic” DLI. We have recently reported that the
intentional induction of mixed lymphohematopoietic
chimerism, with later conversion of the mixed chimeric state
to one of full donor hematopoiesis, results in striking antitu-
mor effects with this novel transplantation strategy [32,33].
This review describes the outcomes of patients who under-
went nonmyeloablative alloSCT for hematologic malignan-
cies that relapsed after autoSCT.
PATIENTS AND METHODS
Thirteen patients with relapsed or refractory hemato-
logic malignancies after autoSCT received an HLA-identical
(at A, B, and DR loci) related-donor SCT based on a non-
myeloablative mixed chimerism protocol conducted at Mass-
achusetts General Hospital, Boston, MA. Written informed
consent was obtained from each patient prior to enrollment
in this Institutional Review Board–approved protocol.
Patient Characteristics
The diagnosis, age, and phase of disease for the 13 HLA-
matched recipients are shown in Table 1. The median age of
the 13 patients was 42.5 years (range, 24-62 years), and the
median time between ﬁrst autoSCT and second alloSCT was
15 months (range, 3-60 months). Six patients had chemo-
therapy-refractory disease at the time of the second alloSCT.
Patient 381 had both untreated relapse of Hodgkin’s disease
and myelodysplastic syndrome; he had multiple poor-risk
cytogenetic abnormalities and transfusion-dependent pancy-
topenia. Eligibility criteria included Eastern Cooperative
Oncology Group (ECOG) performance status of 0, 1, or 2;
Table 1. Patient Characteristics at Second Transplantation*
Time Between
Between AutoSCT and Disease Status at HLA-Identical CMV Status†
Patient No. Age, y Diagnosis AlloSCT, mo Time of AlloSCT Related Donor Recipient Donor
21 35 NHL 45 Refractory Yes Negative Negative
238 27 HD 12 Untreated relapse Yes Negative Positive
329 55 HD 27 Refractory Yes Negative Negative
334 24 HD 16 Refractory Yes Positive Positive
346 46 NHL 6 Refractory Yes Negative Positive
351 43 HD 19 Untreated relapse Yes Negative Positive
352 38 NHL 6 Untreated relapse Yes Negative Negative
368 36 NHL 7 Refractory Yes Positive Positive
381 62 HD, MDS 18 Untreated relapse Yes Positive Positive
395 51 MM 3 Untreated relapse Yes Positive Negative
403 57 NHL 60 Refractory Yes Negative Positive
409 42 NHL 7 Untreated relapse Yes Positive Positive
160 58 MM 40 Partial response Yes Negative Positive
*NHL indicates non-Hodgkin’s lymphoma; HD, Hodgkin’s Disease; MM, multiple myeloma; MDS, myelodysplastic syndrome.
†Seropositivity before alloSCT. 
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age ≤65 years; and adequate organ function. Patients and
their donors were typed for HLA-A and HLA-B using stan-
dard serologic techniques and for HLA-DR and HLA-DQ
using sequence-specific primer (SSP) or sequence-specific
oligonucleotide probe (SSOP) analyses.
Treatment Protocol
Nonmyeloablative Conditioning Therapy. Nonmyeloabla-
tive conditioning therapy consisted of cyclophosphamide,
50 mg/kg per day, administered intravenously on 3 or
4 consecutive days on days –6 or –5 through –3; thymic
irradiation, 700 cGy, given on day –1 in patients who had not
received previous mediastinal radiotherapy; anti-thymocyte
globulin (ATG), 15 to 30 mg/kg, on days –2, –1, and +1 or
–1, +1, +3, and +5; and cyclosporine, 5 mg/kg, administered
intravenously daily beginning on day –1, reduced to
3 mg/kg on day +4, switched to oral administration when
tolerated at a dose of 6 mg/kg every 12 hours, and then
tapered to discontinuation in the absence of GVHD by
≥35 days post SCT. The initial cohort of patients received a
total of 200 mg/kg cyclophosphamide, the dose of which
was later reduced to 150 mg/kg due to the cardiac toxicity
experienced in 2 patients. The dosages of ATG were
changed (currently 20 mg/kg on days –1, +1, +3, and +5) to
reduce toxicity and achieve better donor T-cell depletion.
Because of previous mediastinal radiotherapy, 8 patients did
not receive thymic irradiation.
Bone Marrow Transplantation. A target number of 3 × 108
nucleated cells/kg recipient body wt was collected by mar-
row aspiration in the operating room from donors under
spinal, epidural, or general anesthesia. In the case of minor
ABO incompatibility (n = 3), plasma was removed from
donor marrow before infusion. In the case of major ABO
incompatibility (n = 1), red blood cells were depleted from
the marrow using a CS-3000 cell separator (Baxter-Fenwal,
Round Lake, IL). The median dose of nucleated cells
infused was 2.74 × 108 cells/kg recipient body wt (range,
0.6-12 × 108/kg).
Donor Leukocyte Collection and Infusion. In the absence of
clinically evident GVHD, patients were eligible for “pro-
phylactic” DLI, beginning on day +35 posttransplantation,
in an effort to convert their mixed chimeric state to a state
of full donor hematopoiesis. Unmobilized donor leukocytes
were obtained by leukapheresis using a COBE Spectra cell
separator (Cobe Laboratories, Lakewood, CO) according to
the manufacturer’s instructions. Pheresis durations were 120
to 240 minutes and yielded a median of 1.4 × 108 cells/kg
recipient body wt (range, 0.7-2.0 × 108/kg) mononuclear
cells and 0.8 × 108/kg recipient body wt (range, 0.3-1.1 ×
108/kg) CD3+ T cells. The target number of CD3+ T cells
per infusion given to 7 patients, for conversion of mixed
chimerism to a state of full donor hematopoiesis, ie, prophy-
lactic DLI, was 1 × 107/kg. Greater numbers of CD3+ T cells
(range, 1 × 107-2.98 × 108/kg) were given to 2 patients for
treatment of relapse (therapeutic DLI).
Supportive Care
Patients were cared for either in high-efﬁciency particu-
late air (HEPA)–filtered or laminar air-flow rooms. All
patients had triple-lumen silastic central venous catheters.
Anti-infective measures included co-trimoxazole for Pneumo-
cystis carinii prophylaxis, administered from admission until
day –1, then 3 times weekly following resolution of neu-
tropenia; levoﬂoxacin, 500 mg daily until resolution of neu-
tropenia; ﬂuconazole, 400 mg beginning on day –1, which
was reduced to 200 mg daily on day 0; and intravenous acy-
clovir, 250 mg/m2 every 8 hours beginning on day –1, which
was changed to 400 mg twice daily following resolution of
neutropenia. Febrile neutropenia was treated with broad-
spectrum antibacterial agents, usually consisting of van-
comycin and ceftazidime. All blood products were irradiated
with 2500 cGy using a cesium irradiator and were transfused
through a third-generation leukocyte depletion ﬁlter.
Treatment of acute GVHD consisted of corticosteroids
(methylprednisolone), initially at a dose of 1 to 2 mg/kg,
then tapered as tolerated. Anti–interleukin-2 receptor α
chain (Zenapax; Hofffmann-Laroche, Nutley, NJ) or
anti–tumor necrosis factor α (Remicade; Centicor, Malvern,
PA) monoclonal antibody therapy was used in 2 patients for
steroid-resistant GVHD.
Analyses of Chimerism
Analyses of microsatellite variable number of tandem
repeat (VNTR) or short tandem repeat (STR) markers were
performed on peripheral blood leukocytes from the patients
and their donors prior to BMT. Each assay included mixtures
of pretransplantation donor and recipient DNA at different
ratios, which were used to estimate the percentage of donor
and/or recipient cells present in the posttransplantation sam-
ples. For early patients, CD3-enriched and CD3-depleted
populations were isolated from the peripheral blood using
magnetic cell sorter (MACS) beads (Miltenyi Biotec, Sunny-
vale, CA). Recently, granulocytes (myeloid) were isolated by
centrifugation over a density gradient (Isolymph; Gallard
Schlesinger, Carle Place, NY), after which CD3-enriched
cells (lymphoid) were isolated from the mononuclear cell
population using MACS beads. Weekly microsatellite analy-
ses were performed on day +7 through day +100 posttrans-
plantation on peripheral blood leukocytes and on days +28
and +100 on bone marrow aspirate samples. Peripheral blood
analyses were then performed every 6 months beginning on
day +180 posttransplantation.
RESULTS
Engraftment
All patients engrafted with a median time to an absolute
neutrophil count of greater than 0.5 × 109/L of 13 days
(range, 9-16 days). No patients received recombinant
growth factor support. Median time to a platelet count of
greater than 20 × 109/L was 17 days (range, 10-30 days).
Chimerism Studies
Sequential measurements of donor chimerism revealed
that all patients had initial mixed chimerism in both T-cell
(CD3+) and CD3– or myeloid lineages (Figure 1). Three
patients had spontaneous conversion to full donor chimerism
after transplantation, with evidence of GVHD, and did not
receive prophylactic DLI (patients 160, 352, 368); 3 patients
had sustained mixed chimerism with evidence of GVHD
(patients 238, 346, 351) and did not receive prophylactic DLI
(Table 2). Six of 7 patients who did not have evidence of
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GVHD and received DLI at approximately day +35 for
mixed chimerism either had an increase in donor chimerism
(1 patient) or converted to full donor chimerism (5 patients),
whereas 1 patient lost the graft (Figures 1 and 2 and Table 3).
All but 1 patients had either full donor chimerism or stable
mixed chimerism at last follow-up.
Donor Leukocyte Infusions
Prophylactic DLIs were given to 7 recipients in an effort
to convert their mixed chimeric state to a state of full donor
chimerism (Table 3). Six patients showed conversion of their
mixed chimeric state to a state of full donor hematopoiesis at
a median of 4.5 weeks (range, 4-5 weeks) after 1 DLI. One
patient with treatment-refractory non-Hodgkin’s lymphoma
showed full donor chimerism after DLI and achieved a com-
plete remission without evidence of GVHD. Four patients
developed grades II to IV GVHD following DLI: 2 grade II
and 2 grade IV (Table 3). Severe acute GVHD led to the
death of 1 patient. One patient (patient 381) lost evidence of
donor chimerism despite 2 DLIs on days +42 and +61 post-
transplantation. Six patients were not able to receive prophy-
lactic DLIs, because of the presence of clinical GVHD after
transplantation. Two patients later received either 1 or
2 therapeutic DLIs for treatment of posttransplantation
relapse. One of these patients had 50% to 90% donor
chimerism at the time of her relapse on day +285 posttrans-
plantation. One DLI of approximately 1 × 107 CD3+ T cells/kg
was given on day +307, which resulted in a complete conver-
sion to full donor chimerism (>99% donor hematopoiesis),
but without a measurable antitumor response. The other
patient had full donor chimerism at the time of therapeutic
DLI on day +85 posttransplantation. No antitumor response
from the DLI was observed in this patient.
Transplantation-Related Toxicities
Patients who died in relapse after the allogeneic trans-
plantation were considered to have died of recurrent disease.
One patient developed reversible cyclophosphamide-induced
Table 2. Patient Outcomes After Allogeneic Stem Cell Transplantation*
Donor T-Cell
Chimerism at Acute Acute
Patient Approximately Prophylactic GVHD GVHD Organ(s) Chronic Response at Cause of
No. Diagnosis Day +35, % DLI Pre-DLI Post-DLI Affected GVHD Day +100 OS, mo Death
21 NHL 50-70 Yes 0 0 — 0 CR 39 (Alive)
238 HD 50-90 No (GVHD) Grade II Skin Limited CR 33 (Died) PD/infection
329 HD 30-50 Yes 0 Grade I Skin Extensive CR 10.5 (Died) AMI
334 HD 10-30 Yes 0 Grade IV GI NE NR/PD 3.5 (Died) PD/GVHD
346 NHL 30-90 No (GVHD) Grade III Skin NE NR/PD 3 (Died) PD
351 HD 70-90 No (GVHD) Grade I Skin Limited CR 21 (Alive)
352 NHL 99 No (GVHD) Grade III GI 0 NR/PD 8.5 (Died) PD
368 NHL 99 No (GVHD) Grade II Skin 0 NR/PD 6.5 (Died) PD
381 HD, MDS <1 Yes 0 0 — 0 PD 8.4 (Died) PD
395 MM 90 Yes 0 Grade II Skin Limited CR 14 (Alive)
403 NHL 70-90 Yes 0 Grade IV GI, liver 0 CR 12 (Alive)
409 NHL 30-50 Yes 0 Grade II Liver NE NR/PD 3 (Died) PD
160 MM 99 No (GVHD) Grade III Skin, GI 0 CR 10 (Alive)
*OS indicates overall survival; CR, complete response; PD, progressive disease; AMI, acute myocardial infarction; NE, not evaluable; NR, no
response.
Figure 1. Percentage of donor T-cell (CD3 +) and CD3–-cell or myeloid chimerism as determined by microsatellite analysis of peripheral blood of
the 13 patients. A, Percentage donor chimerism by day 30; B, percentage donor chimerism by day 65; C, percentage donor chimerism by day 100
posttransplantation.
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cardiac toxicity. One patient died of grade IV GVHD follow-
ing 1 prophylactic DLI given for conversion of chimerism.
Six patients had cytomegalovirus (CMV) reactivation associ-
ated with nonspecific symptoms consisting of low-grade
fever, loss of appetite, nausea, and abdominal cramps, but
without evidence of severe end-organ involvement. All of
these patients responded well to ganciclovir therapy. Severe
life-threatening infectious complications were encountered
in only 1 patient, who succumbed to progressive Hodgkin’s
Disease and systemic nocardiosis 33 months after alloSCT
(patient 238). No severe renal, pulmonary, hepatic, or neuro-
logic toxicities were seen in any of the 13 patients.
Toxicity was graded on a 0-to-4 scale, with grades 3 and
4 being severe or fatal, as described [34].
Graft-Versus-Host Disease
Nine patients developed biopsy-confirmed ≥ grade II
acute GVHD: 4 grade II, 3 grade III, and 2 grade IV. Five of
the 9 patients developed GVHD prior to DLI and 4 after
prophylactic DLI given for chimerism conversion (Table 2).
Four of 9 evaluable patients developed chronic GVHD:
3 limited and 1 extensive. Only 1 patient died of GVHD (he
also had progressive disease), whereas the others responded
well to low-dose immunosuppressive therapy.
Response and Survival
Seven of 13 patients achieved a complete remission,
whereas 6 died from progressive disease (Table 2). Three
patients achieved a complete remission without prophylactic
DLI; they all developed GVHD. One of these 3 patients
converted to full donor chimerism (patient 160), and 2
(patients 238, 351) had sustained mixed chimerism beyond
300 days posttransplantation. Of 7 patients who received
prophylactic DLI, 4 achieved a complete response (CR)
(Table 3). One patient with treatment-refractory non-
Hodgkin’s lymphoma developed full donor chimerism after
DLI and achieved a CR without evidence of clinical GVHD
(patient 21). Although 6 of 7 responders developed GVHD,
2 of them had only grade I GVHD (Table 4), which was
treated with low-dose corticosteroids. Figure 3 illustrates
the striking antitumor response in a patient with refractory
multiple myeloma who had undergone 2 previous autoSCTs
(patient 395). Within 2 months after the second autoSCT,
this patient’s serum immunoglobulin (Ig) G level rose to
6000 mg/dL; it was 7980 mg/dL with 20% plasma cells in
the bone marrow at the time of alloSCT. His IgG level
decreased to only 4360 mg/dL at the time of prophylactic
DLI on day +35. Although this patient developed grade II
mucocutaneous GVHD after DLI, he remains in complete
remission 14 months after the alloSCT, with a persistently
stable IgG level of approximately 650 mg/dL and no
detectable M component on serum protein electrophoresis.
Currently, the median overall survival of the 13 patients is
10 months (range, 3-39 months), with probabilities of
disease-free and overall survival at 2 years of 37.5% and 45%,
respectively. The current median progression-free survival
Table 3. Impact of Prophylactic DLI on Chimerism and GVHD
Patient Chimerism Timing Chimerism Chimerism Acute GVHD Chronic
No. Pre-DLI, T Cell of DLI, d Post-DLI Conversion Time Grade (Organs) GVHD Response
21 50%-70% 34 99% 5 weeks 0 0 CR
329 30%-50% 41 99% 5 weeks I (Skin) Extensive CR
334 10%-30% 44 90% 4 weeks IV (Intestine) 0 NR/PD
381 <1% 42 <1% — 0 0 NR/PD
395 90% 35 99% 4 weeks II (Skin) Limited CR
403 70%-90% 36 99% 4 weeks IV (Intestine, liver) 0 CR
409 30%-50% 40 99% 3 weeks II (Liver) 0 NR/PD
Figure 2. The pattern of donor T-cell (CD3 +) chimerism as determined by microsatellite analysis of peripheral blood over time in 7 patients who
received a single prophylactic DLI beginning on day 35 posttransplantation for conversion of mixed chimerism.
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of those achieving a CR is 14 months (range, 10-39 months);
5 are currently alive and their disease is progression free.
One patient died of sudden myocardial infarction at
10.5 months without evidence of recurrent lymphoma; 1 had
recurrent disease at 9.5 months posttransplantation and died
of progressive disease and systemic nocardiosis 33 months
after transplantation. Six patients had no or minimal
response and died of progressive disease; 1 of these patients
also had severe GVHD.
DISCUSSION
Patients with multiple myeloma having a late relapse
(more than 12 months after autoSCT) can sometimes be
salvaged with a second auto- or an alloSCT using an inten-
sive preparative regimen, although toxicity is substantial
[35]. The outcomes of patients with myeloma in early
relapse after autoSCT or lymphoma in relapse after
autoSCT are universally dire. It becomes even more chal-
lenging when the disease at relapse is refractory to chemo-
therapy and radiotherapy. Conventional alloSCT using a
myeloablative conditioning regimen has been associated
with an unacceptably high transplantation-related mortality
in this group of patients [10,12,36-38]. In a Seattle experi-
ence, 14 of 18 (77%) patients with recurrent lymphoma fol-
lowing AuSCT suffered non-relapse mortality when treated
with myeloablative alloSCT [12]. De Lima et al. published
their experience, in which 8 patients received allo-SCT fol-
lowing myeloablative conditioning after failure of AuSCT
for non-Hodgkin’s lymphoma, and 4 patients died of treat-
ment-related causes [10]. In contrast, our nonmyeloablative
alloSCT strategy has been generally well tolerated and can
be extended to older or sicker patients who otherwise would
not be considered for conventional transplantation. In addi-
tion to an acceptably low transplantation-related mortality
rate (7% in this series), our results also demonstrate that sta-
ble engraftment and excellent durable antitumor effects are
achievable in patients with lymphoma or myeloma in relapse
after autoSCT. These outcomes are consistent with the
recently published results of Slavin et al. [39], in which
reduced transplantation-related toxicities in the presence of
antitumor responses were demonstrated in patients who
received alloSCTs following nonmyeloablative conditioning
for relapsed hematologic malignancy after autoSCT. In that
series, 2 of 6 patients in relapse of non-Hodgkin’s lym-
phoma after autoSCT achieved a CR following nonmyelo-
ablative alloSCT, and 4 died of progressive disease. Similar
results were seen in another small study by Anderlini et al.,
in which 6 patients with relapsed Hodgkin’s disease after
autoSCT were treated with nonmyeloablative conditioning
followed by alloSCT [40]. The median age of these
6 patients was relatively young (29 years). Three of the
patients had chemosensitive relapse at the time of trans-
plantation, 2 died of transplantation-related mortality, and
3 achieved a CR. In both groups, full donor chimerism was
seen in the majority of patients following the transplantation,
Table 4. Correlation Between GVHD and Disease Response
No. of Patients No GVHD Grade I Grade II Grade III Grade IV
Complete remission 7 1/7 2/7 2/7 1/7 1/7
Progressive disease 5 1/5 — 1/5 2/5 1/5
Figure 3. Graft-versus-myeloma effect after DLI in a patient with chemotherapy-refractory multiple myeloma who had a severe relapse 3 months
after second autoSCT. A, Kinetics of serum IgG and normalization of marrow cellularity following prophylactic DLI; B, immunoelectrophoresis
showing the gradual disappearance of monoclonal M component.
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which was likely due to more profound host myelosuppres-
sion induced by busulfan (or melphalan) and the lack of
posttransplantation ATG, which is included in our regimen
as a means of depleting donor T cells to allow mixed
chimerism induction and later DLI administration.
The complete response in 7 of our 13 patients with
advanced, often chemorefractory, lymphoma or myeloma
was probably the result of a powerful immune-mediated
GVT effect, given the fact that most patients were previ-
ously deemed resistant to cyclophosphamide, the only
cytoreductive agent used in our conditioning regimen. The
gradual decline to disappearance of a serum IgG monoclo-
nal protein after the administration of prophylactic DLI in
1 patient with myeloma who had relapsed following 2 previ-
ous autoSCTs (Figure 3), in parallel with the disappearance
of evidence of myeloma from the bone marrow, clearly
demonstrates the therapeutic potential of adoptive cellular
immunotherapy (patient 395). Although this patient devel-
oped grade II mucocutaneous GVHD, he remains in com-
plete remission 14 months after the alloSCT. However,
because of the small number of patients and short follow-up
durations, the real impact of DLI on response rate and
progression-free and overall survival as well as the optimal tim-
ing and dosing of DLI remains to be established. Although
4 of 7 complete responders developed ≥ grade II GVHD,
3 patients achieved a CR with no (1 patient) or minimal
(grade I) GVHD (2 patients), suggesting that GVHD and
GVT response are functionally separable in humans. On the
other hand, the presence of clinically evident GVHD in the
5 patients who died from progressive disease suggests that
the development of GVHD does not assure an antitumor
response (Table 4). This lack of antitumor response may
reflect the inability of tumor cells to present antigens to
donor immune cells because of inadequate expression of
critical cell surface molecules such as adhesion molecules
and costimulatory molecules [41-43], or the generalized
immunosuppression induced by GVHD and its treatment.
It is also likely that patients died from rapid disease progres-
sion before GVT effects had a chance to evolve. In a recent
study, it was demonstrated that the time for clonal expansion
of infused donor immune cells may vary according to the
tumor burden and the percentage of host chimerism and
donor T cells and that a critical effector/target ratio of
T cells has to be reached before an overwhelming GVT
response can take place [44].
Childs et al. recently described sustained remissions in a
fraction (3/18) of patients with metastatic renal-cell carci-
noma receiving nonmyeloablative alloSCT [45,46]. In con-
trast to their observation that antihost alloimmune responses
and disease regression occurred only after full donor T-cell
chimerism was achieved, disease response and the develop-
ment of GVHD occurred in 2 of our patients (patients 238,
351) without complete donor chimerism. The gradual
achievement of complete remission in some patients
(patients 329, 395), in concert with progressive conversion
to increased or full donor chimerism, suggests that progres-
sion to donor chimerism may be a marker of GVH reaction
that leads to antitumor responses.
The preclinical animal models on which our nonmye-
loablative treatment protocol is based clearly demonstrated
that the achievement of mixed chimerism assures a state of
bidirectional, ie, donor- and host-specific tolerance [13-
15,17, 47] and thus can serve as an immunologic platform
for the delivery of (delayed) DLI, which can convert the
mixed chimeric state to a state of full donor hematopoiesis
via a GVH reaction, without causing clinical GVHD
[18,19]. In contrast, the occurrence rates of ≥grade II
GVHD in 9 of 13 patients, 5 pre-DLI and 4 post-DLI, were
high. These rates are higher than the previously reported
incidence of GVHD in our other patients on the same treat-
ment protocol who did not have prior autoSCTs [33], and so
are of concern in this patient population. Clearly, the ATG
used in this protocol does not deplete T cells in the donor
marrow in vivo to the same extent as is achieved with mono-
clonal antibodies in the murine models cited above. Possible
reasons for the high incidence of GVHD in these patients
include: (1) the incomplete T-cell depletion of the donor
marrow induced a subclinical GVHD, which was accentu-
ated when DLIs were given, (2) the proinﬂammatory condi-
tions (up-regulation of cell adhesion molecules and various
cytokines and chemokines) that play a role in the pathogen-
esis of acute GVHD are different in heavily pretreated
patients and not as short-lived in duration as in animal mod-
els, and (3) patients who have had a previous autoSCT are
particularly prone to GVHD because of profound host
immunosuppression related to multiple prior therapies.
Interestingly, 12 of 13 patients in this cohort achieved sus-
tained engraftment, which is a substantially higher rate than
that in our entire series. Clearly, the mixed chimeric state
does not always reﬂect a state of GVH tolerance, as 2 of our
patients who had sustained mixed chimerism achieved com-
plete remission with the development of GVHD (patients
238, 351). Despite the increased incidence of acute GVHD
in this cohort of patients, the majority responded well to
treatment, and only 1 patient succumbed to GVHD.
Another important observation was the lack of fatal
infectious complications. Six patients, who had CMV reacti-
vation with nonspeciﬁc symptoms but without any evidence
of end-organ involvement, responded well to ganciclovir
therapy. Except for 1 patient who died of progressive
Hodgkin’s disease and systemic nocardiosis 33 months fol-
lowing alloSCT, fatal fungal or viral infections were not
encountered. This result is probably due to the nonmye-
loablative preparative regimen, which does not signiﬁcantly
violate the mucosal integrity, and to aggressive prophylactic
antiviral and antifungal treatment [48]. Besides, preliminary
studies focusing on the recovery of T cells (their naive ver-
sus memory phenotype), natural killer cells, and B cells sug-
gest that T-cell recovery is fairly rapid in most patients (data
not shown). Studies looking at the impact of DLI on the
evolving immune reconstitution are in progress.
In conclusion, the novel strategy of the deliberate induc-
tion of mixed lymphohematopoietic chimerism with non-
myeloablative conditioning followed by prophylactic DLI is
an effective treatment for selected patients with lymphohe-
matopoietic malignancies in relapse following autoSCT.
Although GVHD risk is high in this patient population, in
most cases it is manageable and has been associated with
durable antitumor responses, even in patients with chemore-
fractory disease. Efforts are underway to discern the mecha-
nisms of GVHD and GVT response in this mixed chimeric
model so that the dissociation of the 2 can be maximized.
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